Skip to main content
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. — Investor Relations & Filings

Ticker · NAGE ISIN · US1710774076 LEI · 529900OPI7B8JPXCVS70 US Manufacturing
Filings indexed 954 across all filing types
Latest filing 2012-02-14 Director's Dealing
Country US United States of America
Listing US NAGE

About Niagen Bioscience, Inc.

https://www.niagenbioscience.com/

Niagen Bioscience, Inc. (formerly ChromaDex) is a bioscience company focused on the science of nicotinamide adenine dinucleotide (NAD+). The company aims to improve healthspan and support healthy aging by developing products that restore and optimize cellular NAD+ levels. Its core proprietary ingredient is Niagen®, a patented and clinically studied form of nicotinamide riboside (NR), a precursor to NAD+. Niagen® is the key component in the company's consumer dietary supplement brand, Tru Niagen®, and is also developed for the food, beverage, and pharmaceutical markets. The company's research is supported by numerous human clinical studies, a portfolio of over 50 owned and licensed patents, and collaborations with global research institutions.

Recent filings

Filing Released Lang Actions
Director's Dealing 2012
Director's Dealing
2012-02-14 English
Director's Dealing 2012
Director's Dealing
2012-02-14 English
Director's Dealing 2012
Director's Dealing
2012-02-14 English
Director's Dealing 2012
Director's Dealing
2012-02-14 English
Director's Dealing 2012
Director's Dealing
2012-02-14 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 14, 2012. It reports on unregistered sales of equity securities and details a private placement and a registered offering of common stock, including amounts raised, share prices, and placement agent fees. The content focuses on financing activities and capital raising events. There are no financial statements or comprehensive financial performance data included, nor is it an announcement of a report publication. The document is not a full annual or quarterly report, nor a management discussion or earnings release. It is a regulatory filing specifically reporting capital raising events and related agreements. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2012-02-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.